Engages in the research and development of RNA-targeted therapeutics. Its pipeline addresses rare diseases, neurological conditions, and cardiovascular disorders. The company applies antisense technology to create treatments that regulate protein production, with several programs advancing through clinical trials.
1989
United States
Biotechnology
See all
Carbon emissions
Electricity consumption
Carbon certificate projects
Targets
SDG Impact
Total sustainability employees
4-6
ⓈThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.Fake Job Title 1
**************
Fake Job Title 2
**************
Disclaimer: The information provided by illuminem ("we", "us") is for general informational purposes only. All information on the pages is provided in good faith, however we make no representation or warranty of any kind, express or implied, regarding the accuracy of any information on the pages. The information on the pages is either provided to us directly by the companies to which the information relates, or by third-party data providers, or derives from publicly available sources. In certain instances the information might be estimations based on limited information publicly available. Your reliance on any information provided on the pages is solely at your own risk. If you believe that any information is incorrect or in breach of your rights, please contact us.